Do Nektar’s disappointing clinical trial results invalidate $2 billion Bristol-Myers deal?
June 04, 2018 at 11:18 AM EDT
Bristol-Myers’ $1.85 billion deal with Nektar, announced in February, is predicated largely on the success of this exact combination of drugs.
